Innate Pharma S.A.
IPHA
$1.93
-$0.04-2.03%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -76.80% | -76.25% | 109.96% | 115.24% | -12.48% |
| Total Other Revenue | -17.45% | -15.50% | 36.34% | 39.77% | 14.89% |
| Total Revenue | -69.63% | -68.91% | 86.95% | 91.66% | -9.89% |
| Cost of Revenue | -8.59% | -6.42% | -3.07% | -0.63% | 28.80% |
| Gross Profit | -289.19% | -293.67% | 77.47% | 76.91% | -56.69% |
| SG&A Expenses | 3.62% | 6.08% | -6.42% | -4.07% | -23.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.84% | -3.61% | -4.00% | -1.59% | 11.84% |
| Operating Income | -6,419.71% | -6,577.19% | 48.12% | 46.81% | -104.80% |
| Income Before Tax | -1,525.37% | -1,559.15% | 84.79% | 84.41% | -72.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,525.37% | -1,559.15% | 84.79% | 84.41% | -72.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,525.37% | -1,559.15% | 84.81% | 84.42% | -72.14% |
| EBIT | -6,419.71% | -6,577.19% | 48.12% | 46.81% | -104.80% |
| EBITDA | -996.99% | -1,018.29% | 50.23% | 48.98% | -71.17% |
| EPS Basic | -1,520.69% | -1,545.22% | 85.01% | 84.63% | -72.45% |
| Normalized Basic EPS | -1,510.96% | -1,543.06% | 62.33% | 61.42% | -79.83% |
| EPS Diluted | -1,673.58% | -1,672.90% | 85.09% | 84.71% | -74.82% |
| Normalized Diluted EPS | -1,614.71% | -1,605.80% | 62.33% | 61.42% | -80.74% |
| Average Basic Shares Outstanding | 0.69% | 0.69% | 1.33% | 1.33% | 0.71% |
| Average Diluted Shares Outstanding | -5.85% | -3.47% | 1.33% | 1.33% | 4.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |